Related Experiment Video
Updated: Jun 10, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Development of aptamer therapeutics
David H J Bunka1, Olga Platonova, Peter G Stockley
1Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK.
Abstract:
The field of aptamer research is growing rapidly, with ∼230 papers using the word 'aptamer' published from January to June 2010. These reports cover many different applications ranging from tools to study protein function to potential diagnostic and therapeutic agents. In this review we will focus on the processes involved in isolating and developing aptamers as therapeutic compounds, using specific examples including the first aptamer therapeutic approved for use in humans (Pegaptanib or Macugen). We will also mention a few of the growing number of aptamer therapeutics in various stages of preclinical and clinical trial.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted

